Provides cancer diagnostic testing services.
Jun 2026Revenue $766M/yrExpenses $835M/yr
Fell below break-even Mar 2020Cash runway over 10 years from Jun 2026
Figures by year
When will Neogenomics be profitable again?
Its expenses passed its revenue in Mar 2020. In the 12 months to Jun 2026, revenue was $766M and expenses $835M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $727M | $843M | −$116M |
| Dec 2024 | $661M | $753M | −$92.1M |
| Dec 2023 | $592M | $699M | −$108M |
| Dec 2022 | $510M | $667M | −$158M |
| Dec 2021 | $484M | $603M | −$119M |
| Dec 2020 | $444M | $458M | −$14.0M |
| Dec 2019 | $409M | $396M | $13.0M |
| Dec 2018 | $277M | $267M | $10.0M |
| Dec 2017 | $240M | $237M | $2.90M |
| Dec 2016 | $232M | $230M | $2.15M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.